image
bioAffinity Technologies, Inc. BIAF
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
Watchlist
$ 0.2044
-44.5 %
$ 3.73 M
Market Cap
-0.28
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one BIAF stock under the worst case scenario is HIDDEN Compared to the current market price of 0.204 USD, bioAffinity Technologies, Inc. is HIDDEN

BIAF Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one BIAF stock under the base case scenario is HIDDEN Compared to the current market price of 0.204 USD, bioAffinity Technologies, Inc. is HIDDEN

BIAF Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one BIAF stock under the best case scenario is HIDDEN Compared to the current market price of 0.204 USD, bioAffinity Technologies, Inc. is HIDDEN

BIAF Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart BIAF

image
1M -152%
6M -541%
1Y -986%
3Y --%
5Y --%
All
$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.8$0.6$0.6$0.4$0.4$0.2$0.215 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
9.36 M REVENUE
269.68%
Growth Rates
1Year 269.68%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-8.95 M OPERATING INCOME
-12.29%
Growth Rates
1Year -12.29%
3Years -59.49%
5Years -23.69%
7Years 0.00%
10Years 0.00%
-9.04 M NET INCOME
100.00%
Growth Rates
1Year 100.00%
3Years 25.99%
5Years 14.87%
7Years 0.00%
10Years 0.00%
-7.26 M OPERATING CASH FLOW
-20.32%
Growth Rates
1Year -20.32%
3Years -52.49%
5Years -23.88%
7Years 0.00%
10Years 0.00%
-79.1 K INVESTING CASH FLOW
96.42%
Growth Rates
1Year 96.42%
3Years 0.00%
5Years -47.31%
7Years 0.00%
10Years 0.00%
5.63 M FINANCING CASH FLOW
1731.26%
Growth Rates
1Year 1731.26%
3Years 19.15%
5Years 19.24%
7Years 0.00%
10Years 0.00%
2.21 M REVENUE
-6.08%
Growth Rates
1Year 269.68%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-2.95 M OPERATING INCOME
-49.28%
Growth Rates
1Year -12.29%
3Years -59.49%
5Years -23.69%
7Years 0.00%
10Years 0.00%
-2.97 M NET INCOME
-48.28%
Growth Rates
1Year 100.00%
3Years 25.99%
5Years 14.87%
7Years 0.00%
10Years 0.00%
-1.68 M OPERATING CASH FLOW
1.88%
Growth Rates
1Year -20.32%
3Years -52.49%
5Years -23.88%
7Years 0.00%
10Years 0.00%
-1 INVESTING CASH FLOW
99.99%
Growth Rates
1Year 96.42%
3Years 0.00%
5Years -47.31%
7Years 0.00%
10Years 0.00%
2.03 M FINANCING CASH FLOW
21.03%
Growth Rates
1Year 1731.26%
3Years 19.15%
5Years 19.24%
7Years 0.00%
10Years 0.00%
Balance Sheet bioAffinity Technologies, Inc.
image
Current Assets 2.7 M
Cash & Short-Term Investments 1.11 M
Receivables 1.14 M
Other Current Assets 451 K
Non-Current Assets 3.82 M
Long-Term Investments 0
PP&E 1.62 M
Other Non-Current Assets 2.2 M
16.97 %17.49 %6.92 %24.86 %33.76 %Total Assets$6.5m
Current Liabilities 3.1 M
Accounts Payable 987 K
Short-Term Debt 694 K
Other Current Liabilities 1.42 M
Non-Current Liabilities 807 K
Long-Term Debt 20.2 K
Other Non-Current Liabilities 787 K
25.24 %17.75 %36.38 %20.11 %Total Liabilities$3.9m
EFFICIENCY
Earnings Waterfall bioAffinity Technologies, Inc.
image
Revenue 9.36 M
Cost Of Revenue 5.98 M
Gross Profit 3.38 M
Operating Expenses 12.3 M
Operating Income -8.95 M
Other Expenses 86.4 K
Net Income -9.04 M
10m10m8m8m6m6m4m4m2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)9m(6m)3m(12m)(9m)(86k)(9m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
36.09% GROSS MARGIN
36.09%
Averages
1Year 36.09%
3Years 52.54%
5Years 31.52%
7Years 0.00%
10Years 0.00%
-95.64% OPERATING MARGIN
-95.64%
Averages
1Year -95.64%
3Years -27974.00%
5Years -16784.40%
7Years 0.00%
10Years 0.00%
-96.56% NET MARGIN
-96.56%
Averages
1Year -96.56%
3Years -56727.07%
5Years -34036.24%
7Years 0.00%
10Years 0.00%
-347.41% ROE
-347.41%
Averages
1Year -347.41%
3Years -194.91%
5Years -99.29%
7Years 0.00%
10Years 0.00%
-138.78% ROA
-138.78%
Averages
1Year -138.78%
3Years -100.75%
5Years -1145.93%
7Years 0.00%
10Years 0.00%
-218.49% ROIC
-218.49%
Averages
1Year -218.49%
3Years -126.09%
5Years 90.92%
7Years 0.00%
10Years 0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis bioAffinity Technologies, Inc.
image
00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)(7m)(7m)(8m)(8m)202020202021202120222022202320232024202420252025
Net Income -9.04 M
Depreciation & Amortization 606 K
Capital Expenditures 0
Stock-Based Compensation 0
Change in Working Capital 0
Others -7.26 M
Free Cash Flow -7.34 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets bioAffinity Technologies, Inc.
image
BIAF has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership bioAffinity Technologies, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
bioAffinity Technologies Announces Pricing of $3.25 Million Offering SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces the pricing of a best efforts offering of securities for aggregate gross proceeds of $3.25 million. businesswire.com - 2 weeks ago
bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies is implementing efficiency measures for CyPath Lung that streamline lab processing and data acquisition and reduce lab costs. businesswire.com - 1 month ago
BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues bioAffinity witnesses record 2024 revenues, driven by CyPath Lung adoption, Medicare coverage and strategic expansion across healthcare networks. zacks.com - 1 month ago
bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024 SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies, Inc. (BIAF) releases financial results for 2024. businesswire.com - 1 month ago
Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies' CyPath Lung test uncovered a hidden second primary lung cancer in a patient who had been treated for lung cancer earlier. businesswire.com - 1 month ago
Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--In another case study, CyPath® Lung helped physicians identify and treat a recurrence of breast cancer in a high-risk patient. businesswire.com - 2 months ago
bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today announced strategic actions to cut $4 million in annual costs at its subsidiary CAP/CLIA pathology laboratory. businesswire.com - 2 months ago
bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of warrant inducement transaction for aggregate gross proceeds of $1.4 million. businesswire.com - 2 months ago
WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million JERSEY CITY, N.J. , Feb. 25, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) has entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 2,438,473 of the Company's shares of common stock (the "Existing Warrants"). prnewswire.com - 2 months ago
bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity has entered into warrant exercise agreements to exercise certain outstanding warrants for gross cash proceeds of $1.4 million. businesswire.com - 2 months ago
Zacks Initiates Coverage of bioAffinity With Neutral Recommendation Discover why Zacks rates bioAffinity as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore BIAF's promising growth prospects and financial health amid market challenges. zacks.com - 3 months ago
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 p.m. accesswire.com - 4 months ago
8. Profile Summary

bioAffinity Technologies, Inc. BIAF

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 3.73 M
Dividend Yield 0.00%
Description bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Contact 22211 West Interstate 10, San Antonio, TX, 78257 https://www.bioaffinitytech.com
IPO Date Sept. 1, 2022
Employees 57
Officers Ms. Julie Anne Overton Director of Communications Mr. Timothy P. Zannes J.D. Executive Vice President, Secretary & General Counsel Ms. Maria Zannes J.D. Founder, President, Chief Executive Officer & Director Mr. Dallas J. Coleman Vice President of sales Dr. William Bauta Ph.D. Chief Science Officer Mr. Steven Girgenti Founder & Executive Chairman of the Board Mr. Xavier T. Reveles M.S. Chief Operating Officer